Hydroxyurea Medac 500 mg kapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

hydroxyurea medac 500 mg kapseli, kova

medac gesellschaft fÜr klinische spezialprÄparate mbh - hydroxyurea - kapseli, kova - 500 mg - hydroksikarbamidi

Oribamide 500 mg kapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

oribamide 500 mg kapseli, kova

orifarm generics a/s - hydroxyurea - kapseli, kova - 500 mg - hydroksikarbamidi

Hydrea 500 mg kapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

hydrea 500 mg kapseli, kova

cheplapharm arzneimittel gmbh - hydroxyurea - kapseli, kova - 500 mg - hydroksikarbamidi

Hydrea 500 mg kapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

hydrea 500 mg kapseli, kova

paranova oy - hydroxyurea - kapseli, kova - 500 mg - hydroksikarbamidi

HYDROXYUREA ORIFARM 500 mg kapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

hydroxyurea orifarm 500 mg kapseli, kova

orifarm oy - hydroxycarbamidum - kapseli, kova - 500 mg - hydroksikarbamidi

Hydrea 500 mg kapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

hydrea 500 mg kapseli, kova

orifarm oy - hydroxyurea - kapseli, kova - 500 mg - hydroksikarbamidi

Adakveo Euroopan unioni - suomi - EMA (European Medicines Agency)

adakveo

novartis europharm limited - crizanlizumab - anemia, sickle cell - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

Jakavi Euroopan unioni - suomi - EMA (European Medicines Agency)

jakavi

novartis europharm limited - ruxolitinibi (fosfaatteina) - myeloproliferative disorders; polycythemia vera; graft vs host disease - antineoplastiset aineet - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. polysytemia vera (pv)jakavi on tarkoitettu aikuisille potilaille, joilla on polysytemia vera, jotka ovat resistenttejä tai intolerantteja ja hydroksiurea. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.

VALCYTE 450 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

valcyte 450 mg tabletti, kalvopäällysteinen

roche oy - valganciclovirum hydrochloridum - tabletti, kalvopäällysteinen - 450 mg - valgansikloviiri

Valganciclovir Sandoz 450 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

valganciclovir sandoz 450 mg tabletti, kalvopäällysteinen

sandoz a/s - valganciclovir hydrochloride - tabletti, kalvopäällysteinen - 450 mg - valgansikloviiri